Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and
preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis
(dcSSc).
Phase:
Phase 2
Details
Lead Sponsor:
Emerald Health Pharmaceuticals Emerald Health Pharmaceuticals Inc.